Nexera Technologies Ltd (NEXR) Stock Competitors & Peer Comparison
See (NEXR) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEXR | $1.10 | +95.56% | 711.8K | -0.01 | -$81.07 | N/A |
| VRTX | $480.18 | +1.05% | 121.9B | 25.51 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $620.14 | -0.53% | 63.9B | 13.59 | $45.63 | +0.58% |
| ARGX | $888.65 | +4.24% | 55B | 80.20 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $293.17 | -0.30% | 39.1B | 52.82 | $5.55 | N/A |
| RVMD | $178.17 | +4.95% | 37.9B | -25.20 | -$7.07 | N/A |
| RVMDW | $8.37 | +11.45% | 37.6B | -2.02 | -$4.15 | N/A |
| ROIV | $34.02 | +0.03% | 24.5B | -37.75 | -$0.90 | N/A |
Stock Comparison
NEXR vs VRTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, VRTX has a market cap of 121.9B. Regarding current trading prices, NEXR is priced at $1.10, while VRTX trades at $480.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas VRTX's P/E ratio is 25.51. In terms of profitability, NEXR's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, NEXR is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check VRTX's competition here
NEXR vs VRNA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NEXR is priced at $1.10, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NEXR's ROE is -0.37%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, NEXR is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check VRNA's competition here
NEXR vs REGN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, REGN has a market cap of 63.9B. Regarding current trading prices, NEXR is priced at $1.10, while REGN trades at $620.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas REGN's P/E ratio is 13.59. In terms of profitability, NEXR's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NEXR is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check REGN's competition here
NEXR vs ARGX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ARGX has a market cap of 55B. Regarding current trading prices, NEXR is priced at $1.10, while ARGX trades at $888.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ARGX's P/E ratio is 80.20. In terms of profitability, NEXR's ROE is -0.37%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, NEXR is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ARGX's competition here
NEXR vs SGEN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NEXR is priced at $1.10, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NEXR's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NEXR is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check SGEN's competition here
NEXR vs ALNY Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ALNY has a market cap of 39.1B. Regarding current trading prices, NEXR is priced at $1.10, while ALNY trades at $293.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ALNY's P/E ratio is 52.82. In terms of profitability, NEXR's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, NEXR is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ALNY's competition here
NEXR vs RVMD Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RVMD has a market cap of 37.9B. Regarding current trading prices, NEXR is priced at $1.10, while RVMD trades at $178.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RVMD's P/E ratio is -25.20. In terms of profitability, NEXR's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NEXR is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RVMD's competition here
NEXR vs RVMDW Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RVMDW has a market cap of 37.6B. Regarding current trading prices, NEXR is priced at $1.10, while RVMDW trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RVMDW's P/E ratio is -2.02. In terms of profitability, NEXR's ROE is -0.37%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, NEXR is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RVMDW's competition here
NEXR vs ROIV Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, NEXR is priced at $1.10, while ROIV trades at $34.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ROIV's P/E ratio is -37.75. In terms of profitability, NEXR's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NEXR is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ROIV's competition here
NEXR vs MRNA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MRNA has a market cap of 23.7B. Regarding current trading prices, NEXR is priced at $1.10, while MRNA trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MRNA's P/E ratio is -7.33. In terms of profitability, NEXR's ROE is -0.37%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, NEXR is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MRNA's competition here
NEXR vs RPRX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RPRX has a market cap of 23.5B. Regarding current trading prices, NEXR is priced at $1.10, while RPRX trades at $54.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RPRX's P/E ratio is 10.79. In terms of profitability, NEXR's ROE is -0.37%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, NEXR is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RPRX's competition here
NEXR vs UTHR Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, NEXR is priced at $1.10, while UTHR trades at $543.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas UTHR's P/E ratio is 20.06. In terms of profitability, NEXR's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NEXR is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check UTHR's competition here
NEXR vs BNTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BNTX has a market cap of 22.8B. Regarding current trading prices, NEXR is priced at $1.10, while BNTX trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BNTX's P/E ratio is -19.48. In terms of profitability, NEXR's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NEXR is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BNTX's competition here
NEXR vs INSM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, INSM has a market cap of 22.6B. Regarding current trading prices, NEXR is priced at $1.10, while INSM trades at $104.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas INSM's P/E ratio is -18.17. In terms of profitability, NEXR's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NEXR is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check INSM's competition here
NEXR vs INCY Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, INCY has a market cap of 21.5B. Regarding current trading prices, NEXR is priced at $1.10, while INCY trades at $107.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas INCY's P/E ratio is 14.45. In terms of profitability, NEXR's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NEXR is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check INCY's competition here
NEXR vs BGNE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NEXR is priced at $1.10, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NEXR's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NEXR is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BGNE's competition here
NEXR vs DNA-WT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NEXR is priced at $1.10, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NEXR's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NEXR is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check DNA-WT's competition here
NEXR vs NBIX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, NBIX has a market cap of 16.5B. Regarding current trading prices, NEXR is priced at $1.10, while NBIX trades at $164.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas NBIX's P/E ratio is 23.73. In terms of profitability, NEXR's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, NEXR is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check NBIX's competition here
NEXR vs ASND Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, NEXR is priced at $1.10, while ASND trades at $261.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ASND's P/E ratio is -108.09. In terms of profitability, NEXR's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NEXR is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ASND's competition here
NEXR vs GMAB Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, GMAB has a market cap of 16B. Regarding current trading prices, NEXR is priced at $1.10, while GMAB trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas GMAB's P/E ratio is 18.81. In terms of profitability, NEXR's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NEXR is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check GMAB's competition here
NEXR vs JAZZ Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, JAZZ has a market cap of 14.2B. Regarding current trading prices, NEXR is priced at $1.10, while JAZZ trades at $226.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas JAZZ's P/E ratio is 17.59. In terms of profitability, NEXR's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, NEXR is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check JAZZ's competition here
NEXR vs BBIO Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BBIO has a market cap of 13.7B. Regarding current trading prices, NEXR is priced at $1.10, while BBIO trades at $69.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BBIO's P/E ratio is -18.64. In terms of profitability, NEXR's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NEXR is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BBIO's competition here
NEXR vs EXEL Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, NEXR is priced at $1.10, while EXEL trades at $53.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas EXEL's P/E ratio is 15.94. In terms of profitability, NEXR's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NEXR is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check EXEL's competition here
NEXR vs IONS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, IONS has a market cap of 12.9B. Regarding current trading prices, NEXR is priced at $1.10, while IONS trades at $78.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas IONS's P/E ratio is -45.55. In terms of profitability, NEXR's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, NEXR is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check IONS's competition here
NEXR vs KRTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NEXR is priced at $1.10, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NEXR's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NEXR is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check KRTX's competition here
NEXR vs AXSM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, AXSM has a market cap of 12.2B. Regarding current trading prices, NEXR is priced at $1.10, while AXSM trades at $237.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas AXSM's P/E ratio is -61.97. In terms of profitability, NEXR's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NEXR is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check AXSM's competition here
NEXR vs MDGL Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, NEXR is priced at $1.10, while MDGL trades at $513.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MDGL's P/E ratio is -40.14. In terms of profitability, NEXR's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, NEXR is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MDGL's competition here
NEXR vs RNAM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NEXR is priced at $1.10, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NEXR's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NEXR is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RNAM's competition here
NEXR vs ARWR Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ARWR has a market cap of 11.2B. Regarding current trading prices, NEXR is priced at $1.10, while ARWR trades at $79.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ARWR's P/E ratio is -36.87. In terms of profitability, NEXR's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NEXR is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ARWR's competition here
NEXR vs BMRN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, NEXR is priced at $1.10, while BMRN trades at $57.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BMRN's P/E ratio is 27.57. In terms of profitability, NEXR's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NEXR is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BMRN's competition here
NEXR vs TECH Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, NEXR is priced at $1.10, while TECH trades at $70.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas TECH's P/E ratio is 153.86. In terms of profitability, NEXR's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NEXR is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check TECH's competition here
NEXR vs SMMT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, SMMT has a market cap of 11B. Regarding current trading prices, NEXR is priced at $1.10, while SMMT trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas SMMT's P/E ratio is -8.86. In terms of profitability, NEXR's ROE is -0.37%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, NEXR is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check SMMT's competition here
NEXR vs KRYS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, NEXR is priced at $1.10, while KRYS trades at $359.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas KRYS's P/E ratio is 46.47. In terms of profitability, NEXR's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NEXR is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check KRYS's competition here
NEXR vs CYTK Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CYTK has a market cap of 10.1B. Regarding current trading prices, NEXR is priced at $1.10, while CYTK trades at $80.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CYTK's P/E ratio is -13.86. In terms of profitability, NEXR's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NEXR is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CYTK's competition here
NEXR vs RXDX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NEXR is priced at $1.10, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NEXR's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NEXR is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RXDX's competition here
NEXR vs CORT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CORT has a market cap of 9.1B. Regarding current trading prices, NEXR is priced at $1.10, while CORT trades at $84.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CORT's P/E ratio is 242.14. In terms of profitability, NEXR's ROE is -0.37%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NEXR is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CORT's competition here
NEXR vs NUVL Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, NEXR is priced at $1.10, while NUVL trades at $123.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas NUVL's P/E ratio is -21.71. In terms of profitability, NEXR's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NEXR is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check NUVL's competition here
NEXR vs ALKS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, NEXR is priced at $1.10, while ALKS trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ALKS's P/E ratio is 55.61. In terms of profitability, NEXR's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, NEXR is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ALKS's competition here
NEXR vs IMGN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NEXR is priced at $1.10, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NEXR's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NEXR is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check IMGN's competition here
NEXR vs HALO Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, HALO has a market cap of 8.6B. Regarding current trading prices, NEXR is priced at $1.10, while HALO trades at $72.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas HALO's P/E ratio is 15.72. In terms of profitability, NEXR's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NEXR is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check HALO's competition here
NEXR vs BPMC Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NEXR is priced at $1.10, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NEXR's ROE is -0.37%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, NEXR is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BPMC's competition here
NEXR vs KYMR Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, KYMR has a market cap of 8.2B. Regarding current trading prices, NEXR is priced at $1.10, while KYMR trades at $116.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas KYMR's P/E ratio is -28.29. In terms of profitability, NEXR's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NEXR is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check KYMR's competition here
NEXR vs APGE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, NEXR is priced at $1.10, while APGE trades at $132.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas APGE's P/E ratio is -30.64. In terms of profitability, NEXR's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NEXR is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check APGE's competition here
NEXR vs TGTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, NEXR is priced at $1.10, while TGTX trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas TGTX's P/E ratio is 18.43. In terms of profitability, NEXR's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, NEXR is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check TGTX's competition here
NEXR vs CERE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NEXR is priced at $1.10, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CERE's P/E ratio is -16.47. In terms of profitability, NEXR's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NEXR is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CERE's competition here
NEXR vs IBRX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, NEXR is priced at $1.10, while IBRX trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas IBRX's P/E ratio is -24.34. In terms of profitability, NEXR's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, NEXR is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check IBRX's competition here
NEXR vs PTGX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, PTGX has a market cap of 7.9B. Regarding current trading prices, NEXR is priced at $1.10, while PTGX trades at $122.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas PTGX's P/E ratio is -67.75. In terms of profitability, NEXR's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NEXR is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check PTGX's competition here
NEXR vs IMVT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, NEXR is priced at $1.10, while IMVT trades at $38.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas IMVT's P/E ratio is -14.32. In terms of profitability, NEXR's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NEXR is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check IMVT's competition here
NEXR vs PCVX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, NEXR is priced at $1.10, while PCVX trades at $53.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas PCVX's P/E ratio is -7.80. In terms of profitability, NEXR's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NEXR is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check PCVX's competition here
NEXR vs MTSR Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NEXR is priced at $1.10, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NEXR's ROE is -0.37%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, NEXR is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MTSR's competition here
NEXR vs RYTM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RYTM has a market cap of 7.4B. Regarding current trading prices, NEXR is priced at $1.10, while RYTM trades at $108.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RYTM's P/E ratio is -34.59. In terms of profitability, NEXR's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, NEXR is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RYTM's competition here
NEXR vs PTCT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, PTCT has a market cap of 7B. Regarding current trading prices, NEXR is priced at $1.10, while PTCT trades at $84.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas PTCT's P/E ratio is -36.27. In terms of profitability, NEXR's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, NEXR is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check PTCT's competition here
NEXR vs PRAX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, NEXR is priced at $1.10, while PRAX trades at $327.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas PRAX's P/E ratio is -24.53. In terms of profitability, NEXR's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NEXR is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check PRAX's competition here
NEXR vs LQDA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, LQDA has a market cap of 6.8B. Regarding current trading prices, NEXR is priced at $1.10, while LQDA trades at $76.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas LQDA's P/E ratio is 549.43. In terms of profitability, NEXR's ROE is -0.37%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, NEXR is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check LQDA's competition here
NEXR vs MRUS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NEXR is priced at $1.10, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NEXR's ROE is -0.37%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, NEXR is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MRUS's competition here
NEXR vs ACLX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NEXR is priced at $1.10, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NEXR's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NEXR is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ACLX's competition here
NEXR vs RETA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NEXR is priced at $1.10, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RETA's P/E ratio is -66.29. In terms of profitability, NEXR's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NEXR is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RETA's competition here
NEXR vs COGT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, NEXR is priced at $1.10, while COGT trades at $38.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas COGT's P/E ratio is -18.01. In terms of profitability, NEXR's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NEXR is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check COGT's competition here
NEXR vs SRRK Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, SRRK has a market cap of 6.4B. Regarding current trading prices, NEXR is priced at $1.10, while SRRK trades at $53.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas SRRK's P/E ratio is -14.98. In terms of profitability, NEXR's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NEXR is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check SRRK's competition here
NEXR vs CGON Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, NEXR is priced at $1.10, while CGON trades at $72.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CGON's P/E ratio is -31.26. In terms of profitability, NEXR's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NEXR is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CGON's competition here
NEXR vs CNTA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NEXR is priced at $1.10, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NEXR's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NEXR is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CNTA's competition here
NEXR vs ABVX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ABVX has a market cap of 6.1B. Regarding current trading prices, NEXR is priced at $1.10, while ABVX trades at $92.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ABVX's P/E ratio is -48.31. In terms of profitability, NEXR's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NEXR is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ABVX's competition here
NEXR vs BLTE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, NEXR is priced at $1.10, while BLTE trades at $149.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas BLTE's P/E ratio is -80.12. In terms of profitability, NEXR's ROE is -0.37%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, NEXR is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check BLTE's competition here
NEXR vs LGND Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, NEXR is priced at $1.10, while LGND trades at $295.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas LGND's P/E ratio is 35.48. In terms of profitability, NEXR's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NEXR is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check LGND's competition here
NEXR vs MIRM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, NEXR is priced at $1.10, while MIRM trades at $117.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MIRM's P/E ratio is -8.62. In terms of profitability, NEXR's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NEXR is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MIRM's competition here
NEXR vs CDTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NEXR is priced at $1.10, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NEXR's ROE is -0.37%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, NEXR is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CDTX's competition here
NEXR vs ABCM Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NEXR is priced at $1.10, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NEXR's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NEXR is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ABCM's competition here
NEXR vs ISEE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NEXR is priced at $1.10, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NEXR's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NEXR is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ISEE's competition here
NEXR vs TVTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, NEXR is priced at $1.10, while TVTX trades at $59.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas TVTX's P/E ratio is -268.32. In terms of profitability, NEXR's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NEXR is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check TVTX's competition here
NEXR vs SYRE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, SYRE has a market cap of 5.4B. Regarding current trading prices, NEXR is priced at $1.10, while SYRE trades at $88.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas SYRE's P/E ratio is -42.63. In terms of profitability, NEXR's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NEXR is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check SYRE's competition here
NEXR vs CAI Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CAI has a market cap of 5.3B. Regarding current trading prices, NEXR is priced at $1.10, while CAI trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CAI's P/E ratio is -102.86. In terms of profitability, NEXR's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NEXR is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CAI's competition here
NEXR vs FBIOX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, NEXR is priced at $1.10, while FBIOX trades at $27.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas FBIOX's P/E ratio is N/A. In terms of profitability, NEXR's ROE is -0.37%, compared to FBIOX's ROE of N/A. Regarding short-term risk, NEXR is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check FBIOX's competition here
NEXR vs LEGN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, NEXR is priced at $1.10, while LEGN trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas LEGN's P/E ratio is -41.81. In terms of profitability, NEXR's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, NEXR is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check LEGN's competition here
NEXR vs APLS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NEXR is priced at $1.10, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas APLS's P/E ratio is 38.35. In terms of profitability, NEXR's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NEXR is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check APLS's competition here
NEXR vs CRSP Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, NEXR is priced at $1.10, while CRSP trades at $53.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CRSP's P/E ratio is -10.56. In terms of profitability, NEXR's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, NEXR is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CRSP's competition here
NEXR vs MANE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MANE has a market cap of 5B. Regarding current trading prices, NEXR is priced at $1.10, while MANE trades at $119.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MANE's P/E ratio is -38.10. In terms of profitability, NEXR's ROE is -0.37%, compared to MANE's ROE of -0.95%. Regarding short-term risk, NEXR is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MANE's competition here
NEXR vs DFTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, NEXR is priced at $1.10, while DFTX trades at $44.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas DFTX's P/E ratio is N/A. In terms of profitability, NEXR's ROE is -0.37%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, NEXR is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check DFTX's competition here
NEXR vs TERN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NEXR is priced at $1.10, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas TERN's P/E ratio is -51.41. In terms of profitability, NEXR's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NEXR is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check TERN's competition here
NEXR vs CELC Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, NEXR is priced at $1.10, while CELC trades at $95.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CELC's P/E ratio is -24.60. In terms of profitability, NEXR's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NEXR is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CELC's competition here
NEXR vs VCYT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, VCYT has a market cap of 4.7B. Regarding current trading prices, NEXR is priced at $1.10, while VCYT trades at $58.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas VCYT's P/E ratio is 29.28. In terms of profitability, NEXR's ROE is -0.37%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, NEXR is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check VCYT's competition here
NEXR vs ERAS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ERAS has a market cap of 4.6B. Regarding current trading prices, NEXR is priced at $1.10, while ERAS trades at $14.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ERAS's P/E ratio is -33.98. In terms of profitability, NEXR's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NEXR is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ERAS's competition here
NEXR vs FOLD Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NEXR is priced at $1.10, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NEXR's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NEXR is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check FOLD's competition here
NEXR vs AKRO Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NEXR is priced at $1.10, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NEXR's ROE is -0.37%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, NEXR is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check AKRO's competition here
NEXR vs EWTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, NEXR is priced at $1.10, while EWTX trades at $41.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas EWTX's P/E ratio is -25.11. In terms of profitability, NEXR's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NEXR is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check EWTX's competition here
NEXR vs XENE Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, NEXR is priced at $1.10, while XENE trades at $56.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas XENE's P/E ratio is -12.08. In terms of profitability, NEXR's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NEXR is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check XENE's competition here
NEXR vs ALPN Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NEXR is priced at $1.10, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NEXR's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NEXR is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ALPN's competition here
NEXR vs KNSA Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, KNSA has a market cap of 4.4B. Regarding current trading prices, NEXR is priced at $1.10, while KNSA trades at $56.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas KNSA's P/E ratio is 64.98. In terms of profitability, NEXR's ROE is -0.37%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, NEXR is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check KNSA's competition here
NEXR vs VKTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, NEXR is priced at $1.10, while VKTX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas VKTX's P/E ratio is -8.93. In terms of profitability, NEXR's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, NEXR is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check VKTX's competition here
NEXR vs OPT Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NEXR is priced at $1.10, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas OPT's P/E ratio is -1.52. In terms of profitability, NEXR's ROE is -0.37%, compared to OPT's ROE of +1.09%. Regarding short-term risk, NEXR is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check OPT's competition here
NEXR vs NAMSW Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, NAMSW has a market cap of 4.2B. Regarding current trading prices, NEXR is priced at $1.10, while NAMSW trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas NAMSW's P/E ratio is -11.83. In terms of profitability, NEXR's ROE is -0.37%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, NEXR is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check NAMSW's competition here
NEXR vs MRTX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NEXR is priced at $1.10, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NEXR's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NEXR is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check MRTX's competition here
NEXR vs ACAD Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, ACAD has a market cap of 4.1B. Regarding current trading prices, NEXR is priced at $1.10, while ACAD trades at $23.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas ACAD's P/E ratio is 11.63. In terms of profitability, NEXR's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NEXR is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check ACAD's competition here
NEXR vs DNLI Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, NEXR is priced at $1.10, while DNLI trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas DNLI's P/E ratio is -8.59. In terms of profitability, NEXR's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NEXR is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check DNLI's competition here
NEXR vs CPRX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, NEXR is priced at $1.10, while CPRX trades at $31.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CPRX's P/E ratio is 11.30. In terms of profitability, NEXR's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NEXR is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CPRX's competition here
NEXR vs DNTH Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, DNTH has a market cap of 3.8B. Regarding current trading prices, NEXR is priced at $1.10, while DNTH trades at $91.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas DNTH's P/E ratio is -22.17. In terms of profitability, NEXR's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NEXR is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check DNTH's competition here
NEXR vs TNGX Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, NEXR is priced at $1.10, while TNGX trades at $30.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas TNGX's P/E ratio is -36.31. In terms of profitability, NEXR's ROE is -0.37%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, NEXR is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check TNGX's competition here
NEXR vs RYZB Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NEXR is priced at $1.10, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NEXR's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NEXR is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check RYZB's competition here
NEXR vs CBAY Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NEXR is priced at $1.10, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NEXR's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NEXR is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check CBAY's competition here
NEXR vs NAMS Comparison June 2026
NEXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEXR stands at 711.8K. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, NEXR is priced at $1.10, while NAMS trades at $31.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEXR currently has a P/E ratio of -0.01, whereas NAMS's P/E ratio is -19.96. In terms of profitability, NEXR's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, NEXR is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for NEXR.Check NAMS's competition here